End of Aduhelm’s road; Janet Wood­cock ex­it in­ter­view; Stu­art Schreiber's $500M ex­per­i­ment; Ver­tex's pain break­through; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Amid a week packed with earn­ings and big news, the End­points team al­so brought a sol­id line­up of orig­i­nal re­port­ing. See if you missed any­thing!

End of Aduhelm’s road

Bio­gen will stop sales and de­vel­op­ment of its con­tro­ver­sial Alzheimer’s drug Aduhelm, walk­ing away from a drug that was ap­proved against out­side ex­perts’ ad­vice, led to con­gres­sion­al in­quiries and faced push­back over its cost and ef­fi­ca­cy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER